← Back to patent-cliff list
Bulevirtide Acetate
Tier C — Watch / tradeBulevirtide Acetate
Inserm
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HBV pol, NTCP
Brand：HEPCLUDEX, Hepcludex
Indications (approved)：慢性丁型肝炎
Regional status
US
Approved
2026-05-22
EU
Approved
2020-07-31
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Bulevirtide Acetate?
Approved indications include: 慢性丁型肝炎.
When does the Bulevirtide Acetate patent expire?
No public expiry year is available for Bulevirtide Acetate yet; this page updates once verified.
How do I get a quote for Bulevirtide Acetate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27